Epcoritamab vs watchful waiting for low-tumor follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new drug called epcoritamab (a type of immunotherapy) to see if it can keep follicular lymphoma under control, compared to 'watch and wait' (monitoring without treatment). If you have low tumor burden and haven't been treated yet, joining this trial might give you early treatment that could improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have follicular lymphoma (grade 1 to 3a) that was diagnosed within the past 6 months.
- You have not had any prior treatment for lymphoma.
- Your lymphoma is at stage II (non-contiguous), III, or IV.
- You have 'low tumor burden' — meaning no large masses, no significant symptoms, and no lymphoma-related fluid buildup or low blood counts.
- You have at least one measurable lymph node or lesion on imaging (CT, PET/CT, or MRI).
- Your overall health is good enough (able to care for yourself, no major organ issues).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medications (obinutuzumab and CC-99282) for people with a type of lymphoma called follicular lymphoma that has not been treated before and is considered high-burden (meaning it is widespread or growing quickly). The goal is to see if this combination helps control the cancer.
This trial tests a drug called epcoritamab for people with follicular lymphoma (a type of slow-growing blood cancer) that improved but did not completely go away after standard first therapy. The goal is to see if epcoritamab can help achieve a complete remission.
This phase 2 trial tests whether a combination of epcoritamab plus rituximab can work as a first treatment for follicular lymphoma. It may help people whose lymphoma is causing symptoms or affecting organs, or who have bulky disease, by targeting the lymphoma cells.
This study looks at how well epcoritamab works for people with diffuse large B-cell lymphoma or follicular lymphoma who have already tried two or more treatments. Researchers want to see how it works in routine care, not in a strict research setting.
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
This trial tests a combination of two drugs — epcoritamab and a gentler chemo regimen (rituximab-mini CVP) — for older or frailer patients with newly diagnosed aggressive B-cell lymphoma who cannot tolerate standard intensive chemo. The goal is to find a safer but effective treatment option that still controls the lymphoma.
Hear when a new Randomized trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.